Association between serum homocysteine level and cognitive impairment in PD patients
10.3969/j.issn.1009-0126.2018.06.019
- VernacularTitle:帕金森病患者认知功能障碍与同型半胱氨酸的相关性研究
- Author:
Quntao YU
1
;
Min KONG
;
Maowen BA
;
Ling YU
;
Guoping YU
;
Hui LIANG
Author Information
1. 264000,烟台市烟台山医院神经内科
- Keywords:
Parkinson disease;
homocysteine;
cognition disorders;
dementia;
levodopa;
benserazide
- From:
Chinese Journal of Geriatric Heart Brain and Vessel Diseases
2018;20(6):631-634
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the association between serum homocysteine (Hcy) level and cognitive impairment in PD patients.Methods Eighty-one PD patients admitted to our hospital were divided into normal cognition group (n=25),mild cognitive impairment group (n=32) and dementia group (n=24) with 19 healthy persons undergoing physical examination served as a control group.Their cognitive impairment was assessed according to their medical history,detailed physical examination data,Hoehn-Yahr scale score,MMSE score,and CDR score.Their serum levels of Hcy,folic acid and vitamin B12 were measured.The association of serum Hcy,folic acid and vitamin B12 levels with cognitive impairment was analyzed.Results The serum Hcy level was significantly higher in normal cognition group,mild cognitive impairment group and dementia group than in control group (P＜0.05,P＜0.01) and in dementia group than in normal cognition group (14.8±3.9 μmol/L vs 12.5±3.3 μmol/L,P＜0.05).The serum Hcy level was associated with oral levodopa and oral benserazide daily dose,oral levodopa and oral benserazide taking time,course of PD and age (r=0.298,P=0.000;r=0.280,P=0.000;r=0.301,P=0.000;r=0.184,P=0.019) but not associated with the severity of PD.Conclusion High serum Hcy level is one of the risk factors for cognitive impairment in PD patients,and control of oral levodopa dose contributes to the prevention and treatment of dementia in PD patients.
